GLP-1 Insurance Coverage in Washington State:
The 2026 Complete Guide

GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, and Zepbound — are among the most prescribed and most discussed medications in the country. They're also among the most complex to navigate from an insurance standpoint. A patient with obesity and diabetes may find the same medication covered under one indication and denied under another. A person with commercial insurance may pay hundreds per month while a neighbor on Medicare pays nothing — or vice versa.

The confusion often comes down to indication: FDA-approved GLP-1 medications have multiple approved uses — type 2 diabetes management, obesity treatment, cardiovascular risk reduction, and obstructive sleep apnea — and insurers treat each indication differently. A plan that refuses to cover Wegovy for weight loss may cover the same drug under a cardiovascular risk reduction indication. Understanding which indication applies to your situation can be the difference between paying $0 and paying $1,350 out of pocket every month.

At Revive Low T Clinic, we prescribe FDA-approved GLP-1 medications for qualified patients and we navigate insurance coverage on your behalf. This guide breaks down carrier by carrier — Premera, Regence, Kaiser, UnitedHealthcare, Aetna, Cigna, Apple Health, and Medicare — so you know exactly what to expect before your first appointment.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications that mimic a natural gut hormone. They slow gastric emptying, reduce appetite, improve blood sugar control, and — in clinical trials — produce significant cardiovascular and metabolic benefits beyond weight loss alone. The four most commonly prescribed in Washington state are:

The Single Biggest Factor: The Indication

Before looking at any specific carrier, understand that the indication — the reason your doctor prescribes the medication — determines whether your insurance covers it, at what tier, and with what prior authorization requirements. Most plans recognize four distinct pathways:

1. Type 2 Diabetes (T2D): The original and most broadly covered indication. Ozempic and Mounjaro are FDA-approved for T2D and are on formulary at most major Washington carriers. Prior authorization typically requires documented HbA1c ≥7% and, in some cases, a prior metformin trial.
2. Obesity / Weight Management: The most contested indication. Coverage requires an Anti-Obesity Medication (AOM) rider on many commercial plans. Without the rider, Wegovy and Zepbound are often excluded entirely. BMI ≥30, or ≥27 with a qualifying comorbidity (hypertension, dyslipidemia, T2D), is the standard threshold.
3. Cardiovascular Risk Reduction: Wegovy received FDA approval for CV risk reduction in adults with obesity and established cardiovascular disease in 2024. This opened a separate, often less restrictive coverage pathway that doesn't require an AOM rider on many plans. If you have a prior MI, stroke, symptomatic atherosclerosis, or heart failure, this may be your best coverage pathway.
4. Obstructive Sleep Apnea (OSA): Zepbound received FDA approval for moderate-to-severe OSA in adults with obesity in late 2024. Several carriers — including Kaiser and UHC — cover Zepbound for OSA without requiring an AOM rider, making this a significant new pathway for patients who have a sleep study confirming AHI ≥15.

Coverage by Carrier: Washington State's 8 Major Plans

Below is a current breakdown of how each major Washington carrier handles GLP-1 coverage as of early 2026. Formularies and prior authorization criteria change frequently — always verify your specific plan before scheduling.

Premera Blue Cross

Premera is Washington's largest commercial carrier and covers GLP-1 medications across multiple indications with clear — if specific — criteria:

• Type 2 Diabetes: Ozempic and Mounjaro are covered with prior authorization. Documentation requires HbA1c ≥7% and evidence of a metformin trial (or documented contraindication). Estimated member cost: $50–150/month.
• Obesity / Weight Management: Coverage is plan-dependent and requires an Anti-Obesity Medication (AOM) rider. Without the rider, weight management GLP-1s are excluded. BMI ≥30 (or ≥27 with a qualifying comorbidity) required. Estimated member cost: $100–250/month with AOM rider.
• Cardiovascular Risk Reduction: Wegovy for CV risk reduction is likely covered on most Premera plans — use established CVD ICD-10 codes (I25.x, Z87.39, etc.) in the PA to route around the AOM rider requirement. Estimated cost: same as obesity tier.

See our complete Premera GLP-1 coverage guide →

Regence BlueCross BlueShield of Washington

Regence updated its GLP-1 policies under Policy DRU787, effective December 2025. Current coverage structure:

• Type 2 Diabetes: Ozempic and Mounjaro covered with PA. Estimated cost: $50–150/month.
• Obesity / Weight Management: Wegovy and Zepbound coverage is plan-dependent and requires an AOM rider. Not available on all employer group plans. Estimated cost: $100–250/month with AOM rider.
• Cardiovascular Risk Reduction: Wegovy for CV risk is covered with prior authorization, often without requiring the AOM rider. PA can be submitted via CoverMyMeds or by fax at (888) 437-1510. Estimated cost: $100–250/month.

See our complete Regence GLP-1 coverage guide →

Kaiser Permanente Washington

Kaiser operates as an integrated HMO with its own formulary and pharmacy, which means outside-Kaiser prescriptions are filled at out-of-network rates. Key points for GLP-1 coverage:

• Type 2 Diabetes: Covered. Kaiser uses Ozempic (not Wegovy) as its preferred semaglutide agent for T2D. Estimated cost: $0–50/month.
• Obesity / Weight Management: Kaiser removed GLP-1 weight management coverage from its base plans in 2025. A separate weight loss rider is required. Strict step therapy applies: patients must complete at least 6 months of semaglutide before Zepbound is considered for obesity. Estimated cost with rider: $25–75/month.
• Obstructive Sleep Apnea: This is a critical pathway for Kaiser members. Zepbound for moderate-to-severe OSA is covered WITHOUT the weight loss rider — the strongest OSA coverage pathway of any major WA carrier. A sleep study confirming AHI ≥15 is required. Estimated cost: $50–150/month.

See our complete Kaiser GLP-1 coverage guide →

UnitedHealthcare

UHC uses OptumRx as its pharmacy benefit manager. GLP-1 approvals tend to be broad in scope — 12-month authorizations are standard — with solid coverage across multiple indications:

• Type 2 Diabetes: Ozempic and Mounjaro covered with 12-month PA approvals. Estimated cost: $50–150/month.
• Obesity / Weight Management: Wegovy and Zepbound are an optional benefit — some employer group plans set the BMI threshold at ≥40 for Wegovy. Check your specific plan's Summary of Benefits. Estimated cost: $100–250/month.
• Cardiovascular Risk Reduction: Wegovy for CV risk covered with PA. Estimated cost: $100–250/month.
• Obstructive Sleep Apnea: Zepbound for OSA is covered. A sleep study confirming AHI ≥15 is required. Compounded GLP-1s are explicitly excluded on all UHC plans. Estimated cost: $100–250/month.

See our complete UnitedHealthcare GLP-1 coverage guide →

Aetna

Aetna uses CVS Caremark as its PBM. A significant formulary change took effect in 2025 that affects tirzepatide (Zepbound) coverage for obesity specifically:

• Type 2 Diabetes: Covered under CPB 1014 criteria — the same clinical policy bulletin governing TRT. HbA1c documentation required. Estimated cost: $50–150/month.
• Obesity / Weight Management: Wegovy is the preferred anti-obesity GLP-1 and is covered with an AOM rider. Zepbound was removed from Aetna's standard formulary in July 2025 — to get Zepbound covered for obesity, patients must show either a 12–16 week Wegovy trial with less than 5% weight loss, or documented semaglutide intolerance. Estimated cost: $100–250/month for Wegovy; non-formulary status for Zepbound obesity.
• Cardiovascular Risk Reduction: Wegovy for CV risk is covered without requiring an AOM rider. Estimated cost: $100–250/month.
• Obstructive Sleep Apnea: Zepbound's OSA pathway is NOT affected by Aetna's July 2025 formulary removal — it remains covered through a separate clinical pathway.

See our complete Aetna GLP-1 coverage guide →

Cigna

Cigna uses Express Scripts as its PBM and has some of the most specific continuation criteria of any major carrier:

• Type 2 Diabetes: Covered with standard PA. Estimated cost: $50–150/month.
• Obesity / Weight Management: Initial approvals are for 8 months (not the 12-month standard elsewhere). Continuation requires documented ≥5% body weight loss. Semaglutide-first step therapy is required — Zepbound will not be approved for obesity until a Wegovy trial has failed. Estimated cost: $100–250/month.
• Cardiovascular Risk Reduction: Covered, but Cigna's criteria are narrower than most: a prior MI, stroke, or symptomatic peripheral arterial disease must be documented. General atherosclerosis risk is not sufficient. Prescribers must have "specialized skills" in metabolic medicine — Revive's physicians qualify. Estimated cost: $100–250/month.
• Obstructive Sleep Apnea: Zepbound for OSA does not require an AOM rider on Cigna plans. Estimated cost: $100–250/month.

See our complete Cigna GLP-1 coverage guide →

Molina Healthcare (Washington Apple Health / Medicaid)

Washington Apple Health is Washington state's Medicaid program. Molina is one of its managed care organizations. Coverage is governed by the Washington Health Care Authority (HCA) Preferred Drug List:

• Type 2 Diabetes: Ozempic and Mounjaro are fully covered with no cost-sharing. Estimated cost: $0–3/month (nominal copay).
• Obesity / Weight Management: Wegovy and Zepbound are non-preferred on the WA HCA Preferred Drug List. Step therapy requiring failure of at least two preferred agents is required before these medications are approved. Estimated cost after step therapy: $0–3/month.
• Cardiovascular Risk Reduction: Federally required coverage for cardiovascular indications, effective March 2024. Estimated cost: $0–3/month.
• Obstructive Sleep Apnea: Federally required coverage for OSA indication, effective December 2024. Estimated cost: $0–3/month.

Note: Revive Low T Clinic is an out-of-network provider for Apple Health. Patients with Medicaid may face access limitations. Contact us to discuss options.

Medicare Part D

Medicare GLP-1 coverage has a significant statutory limitation for weight loss — and meaningful new pathways that opened in 2024:

• Type 2 Diabetes: Ozempic and Mounjaro are covered on more than 90% of Medicare Part D plans. This is the most straightforward GLP-1 pathway for Medicare beneficiaries. Estimated cost under $2,100 OOP cap (2026): varies by plan.
• Obesity / Weight Management: Medicare Part D is statutorily prohibited from covering weight loss medications under 42 U.S.C. §1395w-102(e)(2). This is a federal law — not a plan decision — and cannot be appealed. However, the CMS BALANCE Model pilot program, expected to launch July 2026, may provide approximately $50/month coverage for beneficiaries with BMI ≥27 plus CVD, prediabetes, or hypertension.
• Cardiovascular Risk Reduction: Wegovy for CV risk is covered if the specific Part D plan lists it on formulary. Coverage varies by plan — check your plan's formulary specifically.
• Obstructive Sleep Apnea: Zepbound for OSA is covered if the specific Part D plan lists it. Again, formulary-dependent.

See our complete Medicare GLP-1 coverage guide →

What If Your Insurance Doesn't Cover It?

If your plan excludes GLP-1 coverage for your indication, or if you're uninsured, there are meaningful ways to reduce the cost. Here's a realistic picture of what these medications cost through each channel:

Compounded Semaglutide & Tirzepatide Pricing

Revive also offers compounded semaglutide and tirzepatide through licensed compounding pharmacy partners (including Hallandale and other options). Compounded medications are dispensed as Flex-Dose vials and shipped directly to you. These are pure formulations — no B12 or niacinamide added. Pricing below is physician (wholesale) pricing; a 3% fee applies for credit card payments.

Physician pricing. 3% fee added for credit card payments. Shipped 2-day or overnight. Multiple pharmacy partners available.

What You Need to Know Before Your Appointment

Coming prepared to your first visit dramatically speeds up the prior authorization process. Here's what to bring and what to be ready to discuss:

Bring to your appointment:

• Your insurance card (front and back) — we'll verify your formulary and benefit structure
• Any recent lab work, especially HbA1c, fasting glucose, lipid panel, and metabolic panel
• A list of current medications (prior GLP-1 use, or prior anti-obesity medication trials, is highly relevant)
• Sleep study results if you have them — AHI ≥15 opens the OSA pathway
• Any prior authorization denial letters — these help us craft an appeal
• Documentation of comorbidities: prior MI, stroke, PAD, heart failure, hypertension, dyslipidemia

Questions to ask your insurance before the visit:

• Does my plan include an Anti-Obesity Medication (AOM) rider?
• Are GLP-1 medications covered for cardiovascular risk reduction without an AOM rider?
• Is Zepbound covered for obstructive sleep apnea under my plan?
• What is the prior authorization process and typical turnaround time?
• What is my current deductible status and estimated copay for a Tier 3 specialty medication?

Why Revive Low T Clinic for GLP-1 Management?

GLP-1 therapy rarely exists in isolation — particularly for men. Obesity, cardiovascular risk, and sleep apnea frequently co-occur with low testosterone, and treating only one piece of the puzzle leads to incomplete results. Revive takes an integrated approach:

• Complete metabolic evaluation: Our comprehensive first-visit lab panel covers HbA1c, fasting glucose, lipid panel, liver enzymes, thyroid, complete metabolic panel, and full hormone panel — everything needed to document medical necessity for GLP-1 therapy and identify concurrent hormonal issues.
• Integrated hormone management: Many GLP-1 patients also have suboptimal testosterone levels. Optimizing testosterone alongside GLP-1 therapy preserves lean muscle mass during weight loss — a critical advantage that most weight loss clinics overlook.
• Flexible prescribing pathways: We prescribe FDA-approved GLP-1 medications — Ozempic, Wegovy, Mounjaro, and Zepbound — through licensed retail pharmacies, making your insurance benefit and manufacturer copay cards applicable. We also offer compounded semaglutide and tirzepatide through licensed pharmacy partners for patients who prefer a cash-pay option or are waiting for PA approval.
• Full PA support: Our team handles prior authorization submission, clinical documentation, and appeals. We review all applicable indications — T2D, obesity, CV risk, and OSA — to find the coverage pathway with the lowest patient cost.

Frequently Asked Questions

Can my doctor prescribe Ozempic for weight loss even though it's approved for diabetes?

Yes — off-label prescribing is legal and common. However, insurance coverage is tied to the FDA-approved indication and your plan's formulary. Prescribing Ozempic off-label for weight loss when you don't have type 2 diabetes will almost certainly result in a prior authorization denial unless your plan has an AOM rider covering it. Wegovy — the weight-management-approved version of the same molecule — is the appropriate on-label prescription for obesity.

My plan denied GLP-1 coverage for weight loss. Are there other options?

Several. First, check whether you qualify under a cardiovascular indication (established heart disease, prior MI, stroke, or symptomatic atherosclerosis) — Wegovy's CV approval often provides a separate, non-excluded pathway. Second, if you have obstructive sleep apnea with AHI ≥15 and a BMI that qualifies, Zepbound's OSA indication may be covered without an AOM rider. Third, if all insurance pathways are exhausted, Eli Lilly's Lilly Direct program offers Zepbound single-dose vials at approximately $349/month with no insurance required. Fourth, Revive offers compounded semaglutide and tirzepatide through licensed compounding pharmacy partners — see the cash-pay pricing table above.

What is an AOM rider and does my employer plan have one?

An Anti-Obesity Medication (AOM) rider is an optional benefit add-on that employers purchase to extend their employees' health coverage to include prescription weight loss medications. Because GLP-1 medications for obesity are expensive, many employers opt out of the AOM rider to control premium costs. To find out if your plan includes it, call the member services number on your insurance card and ask specifically: "Does my plan include coverage for anti-obesity medications, including GLP-1 receptor agonists for weight management?"

Are compounded semaglutide or tirzepatide available?

Yes — Revive offers compounded semaglutide and tirzepatide through licensed compounding pharmacy partners, including Hallandale Pharmacy. These are pure formulations (no B12 or niacinamide added), dispensed as Flex-Dose vials and shipped directly to you. Compounded GLP-1s are cash-pay only — they are not covered by insurance under any carrier. They are a practical option for patients whose insurance doesn't cover GLP-1s for weight loss, or who want to start treatment while awaiting prior authorization. See the pricing table in the Cash-Pay section above.

How long does prior authorization take for GLP-1 medications?

Standard PA turnaround is 3–5 business days for most Washington carriers. Urgent PA requests (for clinically urgent situations) can be processed in 24–72 hours. Regence and UHC tend to be faster; Cigna's 8-month initial approval cycle means the first approval is standard but continuation requires documented weight loss. Our team submits PA paperwork on the day of your visit and tracks the status through approval.

Can I use a manufacturer savings card if I have insurance?

If you have commercial (non-government) insurance, yes — manufacturer copay assistance programs from Novo Nordisk and Eli Lilly can reduce your out-of-pocket cost to as low as $25/month in many cases. These programs are not available to Medicare or Medicaid beneficiaries due to federal anti-kickback regulations. If you have commercial insurance and your plan requires cost-sharing for GLP-1 medications, ask us about manufacturer copay card enrollment at your visit.

*This article is for educational purposes and reflects coverage information as of March 2026. Insurance formularies and prior authorization criteria change frequently. Always verify your specific plan's coverage directly with your insurer. Revive Low T Clinic — 206-960-4770 — revivelowt.com*